Literature DB >> 2992084

Genomic diversity of human T-lymphotropic virus type III (HTLV-III).

F Wong-Staal, G M Shaw, B H Hahn, S Z Salahuddin, M Popovic, P Markham, R Redfield, R C Gallo.   

Abstract

The DNA genomes of human T-lymphotropic virus type III (HTLV-III) isolated from 18 individuals with AIDS or who were at risk for AIDS were evaluated for evidence of variation. Although all of the 18 viral DNA's hybridized throughout their entire genomes to a full-length cloned probe of the original HTLV-III isolate, each of the 18 isolates showed a different restriction enzyme pattern. The number of restriction site differences between isolates ranged from only 1 site in 23 to at least 16 sites in 31. No particular viral genotype was associated with a particular disease state and 2 of the 18 patients had evidence of concurrent infection by more than one viral genotype. Propagation of three different viral isolates in vitro for up to 9 months did not lead to detectable changes in their restriction patterns. These findings indicate that different isolates of HTLV-III comprise a spectrum of highly related but distinguishable viruses and have important implications regarding the pathogenicity of HTLV-III and attempts to develop effective diagnostic, therapeutic, and preventive measures for this virus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2992084     DOI: 10.1126/science.2992084

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  75 in total

1.  Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method.

Authors:  C López-Galíndez; J M Rojas; R Nájera; D D Richman; M Perucho
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

2.  High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells.

Authors:  F Boulerice; S Bour; R Geleziunas; A Lvovich; M A Wainberg
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

3.  New cholesterol-specific antibodies remodel HIV-1 target cells' surface and inhibit their in vitro virus production.

Authors:  Zoltán Beck; Andrea Balogh; Andrea Kis; Emese Izsépi; László Cervenak; Glória László; Adrienn Bíró; Károly Liliom; Gábor Mocsár; György Vámosi; George Füst; Janos Matko
Journal:  J Lipid Res       Date:  2009-08-04       Impact factor: 5.922

4.  Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

Authors:  B A Watkins; M S Reitz; C A Wilson; K Aldrich; A E Davis; M Robert-Guroff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

Review 5.  AIDS and the lung: update 1995. 4. Role of the human immunodeficiency virus within the lung.

Authors:  J R Clarke; D S Robinson; R J Coker; R F Miller; D M Mitchell
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

6.  Similar replication capacities of primary human immunodeficiency virus type 1 isolates derived from a wide range of clinical sources.

Authors:  W Lu; J M Andrieu
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

7.  Quasispecies and naturally occurring superinfection in feline immunodeficiency virus infection.

Authors:  M T Kyaw-Tanner; W F Robinson
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

8.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

9.  Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain.

Authors:  R W Doms; P L Earl; S Chakrabarti; B Moss
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

10.  Two highly antigenic sites in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  E Björling; C A Boucher; A Samuelsson; T F Wolfs; G Utter; E Norrby; F Chiodi
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.